Get the Stockscreener App
1.94
8.06%
-0.17
After Hours:
2.00
0.06
+3.09%
Ironwood Pharmaceuticals Inc stock is traded at $1.94, with a volume of 9.31M.
It is down -8.06% in the last 24 hours and down -56.89% over the past month.
See More
Previous Close:
$2.11
Open:
$2.14
24h Volume:
9.31M
Relative Volume:
4.34
Market Cap:
$586.50M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
48.50
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
-15.65%
1M Performance:
-56.89%
6M Performance:
-68.04%
1Y Performance:
-86.95%
1-Day Range:
$1.8909
$2.14
1-Week Range:
$1.8909
$2.54
52-Week Range:
$1.8909
$15.70
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.94 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
IRWD Shares Experience Decline in Value - Knox Daily
Ironwood Pharmaceuticals stock falls as it exits S&P SmallCap 600 - MSN
STATE STREET CORP Reduces Stake in Ironwood Pharmaceuticals Inc - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 1-Year Low Following Analyst Downgrade - MarketBeat
Ironwood Pharmaceuticals Inc Inc. (IRWD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
What was Ironwood Pharmaceuticals Inc (IRWD)’s performance in the last session? - US Post News
Leerink Partnrs Has Negative Estimate for IRWD Q4 Earnings - MarketBeat
JMP Securities Has Lowered Expectations for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price - MarketBeat
Leerink Partnrs Brokers Lower Earnings Estimates for IRWD - Defense World
JMP Securities Cuts Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target to $14.00 - Defense World
Ironwood Pharmaceuticals Announces Workforce Reduction and Executive Appointment - Defense World
Leerink Partnrs Has Bearish Estimate for IRWD Q4 Earnings - Defense World
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 52-Week Low After Analyst Downgrade - Defense World
Pacer Advisors Inc. Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Vanguard Group Inc Reduces Stake in Ironwood Pharmaceuticals Inc - GuruFocus.com
Investors irked by Ironwood cuts to future-proof company - The Pharma Letter
Ironwood focuses on apraglutide amid workforce cuts - MSN
Ironwood stock target cut to $14 by JMP Securities - MSN
Ironwood Pharmaceuticals stock tumbles following workforce cuts and revenue guidance - MSN
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - Yahoo Finance
Ironwood chops half of staff as 2025 guidance disappoints - PharmaLive
Ironwood Pharmaceuticals to Slash Half of Workforce, Drop Phase 2 Testing of Drug; Issues 2025 Outlook - Marketscreener.com
Ironwood Pharmaceuticals announces workforce reduction - MSN
Ironwood Pharma Announces Major Workforce Cuts and CFO Change - TipRanks
Ironwood Pharmaceuticals announces workforce reduction By Investing.com - Investing.com Nigeria
Ironwood Pharma drops 7% as FY 2025 revenue guidance below consensus - MSN
Ironwood Pharmaceuticals, Inc. Approves A Reduction in the Workforce of Approximately 50% - Marketscreener.com
Ironwood Pharmaceuticals, Inc. Announces Executive Changes -January 29, 2025 at 04:05 pm EST - Marketscreener.com
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $10.00 - Defense World
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 6.4% HigherStill a Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $10.00 Average Target Price from Brokerages - MarketBeat
Bladder Pain Syndrome Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Watson Pharma, Urigen, Allergan, Pfizer, Mundipharma Research GmbH, Ironwood Pharma, Astellas Pharma - The Globe and Mail
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Lowered to $8.00 at Craig Hallum - MarketBeat
IRWD (Ironwood Pharmaceuticals) Cash From Discontinued Inve - GuruFocus.com
IRWD (Ironwood Pharmaceuticals) Net Income From Continuing Operations : $-3.1 Mil (TTM As of Sep. 2024) - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7%Should You Sell? - MarketBeat
Ironwood Pharmaceuticals (IRWD) Stock Dips Amidst Market Volatility - GuruFocus.com
Short Bowel Syndrome Pipeline Trends 2024: Clinical Trials, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments by DelveInsight | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire - Barchart
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Position Reduced by Harbor Capital Advisors Inc. - Defense World
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Down -69.69% This Year: What Is Going To Happen Next - Stocks Register
Zacks Research Issues Optimistic Estimate for IRWD Earnings - Defense World
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 8.7%What's Next? - MarketBeat
Gastroesophageal Reflux Disease Therapeutics Market Top - openPR
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Principal Financial Group Inc. - Defense World
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):